Hospital pharmacy leaders are working on drug supply mitigation strategies every day, but they might be underutilizing their pharmacy technicians when it comes to spotting new shortages.
Three of Mon Health System's four hospitals are implementing a software that uses barcoding and cameras to verify sterile compounding doses, the Morgantown, W.Va.-based system said Aug. 9.
Emergent BioSolutions, a Gaithersburg, Md.-based company that makes multiple vaccines and achieved the first FDA approval for an over-the-counter naloxone nasal spray, plans to reduce operations at three facilities, lay off about 400 workers and cut its COO role.
Novo Nordisk's Wegovy, a weight loss drug, showed a 20 percent reduction in major adverse cardiovascular events in a phase 3 trial, the drugmaker said Aug. 8.
After the FDA approved a Sage Therapeutics drug for postpartum depression but not major depression on Aug. 4, the company delayed announcing its list price and the CFO hinted that Sage is considering reducing its workforce and pipeline.
Private equity firms and hospitals are investing in compounding pharmacies as hundreds of drug shortages afflict healthcare, The Wall Street Journal reported Aug. 7.
More than 90 percent of pharmacists at a Veterans Affairs hospital in Tampa, Fla., who are part of the American Federation of Government Employees passed a vote of no confidence in their leaders Aug. 4, the Tampa Bay Times reported.
Leigh Briscoe-Dwyer, PharmD, the system pharmacy director of United Health Services' hospitals in Johnson City, N.Y., is now president of the American Society of Health-System Pharmacists.
The first pill to treat postpartum depression was approved by the FDA Aug. 4, offering a new treatment option for about 500,000 women who develop the condition annually.
